أخبار السوق اليوم — عناوين الأسهم والعملات الرقمية المنتقاة بالذكاء الاصطناعي

The US FDA has announced a crackdown on copycat weight-loss drugs, specifically targeting Hims & Hers, a telehealth company that has undercut Novo Nordisk's obesity shot prices, raising concerns about regulatory compliance and market competition.

The Dow Jones Industrial Average surpassed the 50,000 mark, driven by a rally in chip stocks, particularly Nvidia, AMD, and Broadcom, due to increased spending on AI data centers by Amazon and Alphabet.

Novo Nordisk shares experienced a rally after the FDA chief threatened to block a copycat version of their drug, potentially favoring the Danish drugmaker in a dispute.

Eli Lilly's weight loss pill is on track for a second-quarter launch in the US, pending FDA approval, with the company expressing optimism about the progress.

The FDA rejected AstraZeneca's subcutaneous version of its lupus medicine, potentially impacting the company's revenue and market share in the lupus treatment market.

ImmunityBio's stock soars after the FDA outlines a resubmission path for ANKTIVA in bladder cancer, indicating a positive development for the company's plans.

ImmunityBio's stock is experiencing a sharp rally after the FDA outlined a resubmission path for its ANKTIVA treatment in bladder cancer, boosting investor sentiment.

Biotics AI, a winner of the TechCrunch Disrupt Battlefield 2023, has received FDA approval for its AI-powered fetal ultrasound product, enhancing detection capabilities for fetal abnormalities.

Akeso's CFO expresses confidence in the company's cancer drug ivonescimab receiving FDA approval, citing a positive outlook for the regulatory process.

US stocks ended higher on Thursday, driven by strong earnings from banks such as Morgan Stanley and Goldman Sachs, as well as a boost from Taiwan-based chipmaker TSMC.

State Street is expanding its services into crypto and tokenized assets, while the FDA has delayed its review of several drugs from Eli Lilly, Sanofi, and Disc Medicine, impacting healthcare stocks.

Regeneron's Chief Scientific Officer George Yancopoulos discussed the company's hearing loss gene therapy and weight loss drugs at the JP Morgan healthcare conference, highlighting the FDA's response and future plans.